TY - JOUR
T1 - Consensus statement regarding storage and reuse of previously reconstituted neuromodulators
AU - Alam, Murad
AU - Bolotin, Diana
AU - Carruthers, Jean
AU - Hexsel, Doris
AU - Lawrence, Naomi
AU - Minkis, Kira
AU - Ross, Edward Victor
PY - 2015/3/15
Y1 - 2015/3/15
N2 - BACKGROUND: Legacy recommendations suggest that vials of botulinum toxin be used within 24 hours of reconstitution and in a single patient. Current standard of care is consistent with storage after reconstitution and use of a single vial for several patients. OBJECTIVE: To develop expert consensus regarding the effectiveness and safety of storage and reuse of botulinum toxin. MATERIALS AND METHODS: The American Society for Dermatologic Surgery authorized a task force of content experts to review the literature and provide guidance. Data extraction was followed by clinical question review, a consensus Delphi process, and validation of the results by peer review. RESULTS: After 2 rounds of Delphi process, the task force concluded by unanimous consensus and with the highest level of confidence that a vial of toxin reconstituted appropriately can, for facial muscle indications, be (1) refrigerated or refrozen for at least 4 weeks before injection without significant risk for contamination or decreased effectiveness and (2) used to treat multiple patients, assuming appropriate handling. CONCLUSION: The standard of care, which allows for use of botulinum toxin more than 24 hours after reconstitution and in more than 1 patient per vial, is appropriate and consistent with the safe and effective practice of medicine.
AB - BACKGROUND: Legacy recommendations suggest that vials of botulinum toxin be used within 24 hours of reconstitution and in a single patient. Current standard of care is consistent with storage after reconstitution and use of a single vial for several patients. OBJECTIVE: To develop expert consensus regarding the effectiveness and safety of storage and reuse of botulinum toxin. MATERIALS AND METHODS: The American Society for Dermatologic Surgery authorized a task force of content experts to review the literature and provide guidance. Data extraction was followed by clinical question review, a consensus Delphi process, and validation of the results by peer review. RESULTS: After 2 rounds of Delphi process, the task force concluded by unanimous consensus and with the highest level of confidence that a vial of toxin reconstituted appropriately can, for facial muscle indications, be (1) refrigerated or refrozen for at least 4 weeks before injection without significant risk for contamination or decreased effectiveness and (2) used to treat multiple patients, assuming appropriate handling. CONCLUSION: The standard of care, which allows for use of botulinum toxin more than 24 hours after reconstitution and in more than 1 patient per vial, is appropriate and consistent with the safe and effective practice of medicine.
UR - http://www.scopus.com/inward/record.url?scp=84924991725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924991725&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000000303
DO - 10.1097/DSS.0000000000000303
M3 - Article
C2 - 25705950
AN - SCOPUS:84924991725
VL - 41
SP - 321
EP - 326
JO - Dermatologic Surgery
JF - Dermatologic Surgery
SN - 1076-0512
IS - 3
ER -